Given that CD97 activates ERK, protein kinase B/Akt, or RhoA signaling pathways in prostate cancer cells, researchers further explored whether the binding of CD55 to CD97 could activate the same signaling pathways in leukocytes. This evidence concerns the gene AKT1 and prostate cancer.